Q-omics provides the consensus-scored CHL1 profile across patient tissues and cancer cell-line models. CHL1 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CHL1 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CHL1 protein abundance shows 23,149 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, KIRC, and GBM as cancer lineages where CHL1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHL1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHL1 survival associations across molecular data types. CHL1 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHL1 RNA expression–survival associations across cancer types. High CHL1 expression shows unfavorable associations in BLCA and UCEC, but favorable associations in UVM, KIRP, MESO and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CHL1 RNA expression.
This table summarizes CHL1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CHL1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHL1 shows lower tumor expression in KIRC, COAD, HNSC, KICH, BRCA and UCEC. The KIRC box plot shows higher CHL1 RNA expression in normal versus tumor tissue (log2 FC = −3.355, t-test p < 0.001).
This table shows molecular features associated with CHL1 in patient tissues and cancer cell lines. In patient samples, CHL1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CHL1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
